Ticagrelor Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Ticagrelor Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Ticagrelor, a drug commonly used as a platelet aggregation inhibitor, received approval from U.S. Food and Drug Administration (USFDA) in July 2011 and in the European Union by the European Commission in December, 2010. Ticagrelor is used for the prevention of thrombotic events such as stroke or heart attack in people with acute coronary syndrome or myocardial infarction with ST wave elevation.
Market Dynamics
Rising prevalence of cardiovascular diseases is attributed to rising geriatric population and changing lifestyles. According to World Health Organization (WHO), around 17.9 million people every year die due to cardiovascular diseases (CVDs), which is about 31% of all global deaths. This is expected to positively impact growth of the ticagrelor market over the next decade.
Furthermore, in September 2016, WHO launched the Global Hearts Initiative through which WHO is supporting governments around the world to improve efforts on CVD prevention and control. Thus, increasing number of non-government and government initiatives, in order to aid in prevention of CVD is expected to help in propelling growth of the ticagrelor market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the ticagrelor market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global ticagrelor market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, ANHUI HAIKANG PHARMACEUTICAL CO., LTD., Avra Laboratories Pvt Ltd., and Sun Pharmaceutical Industries Ltd
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global ticagrelor market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for ticagrelor market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Ticagrelor Market, By Strength:
60 mg
90 mg
Global Ticagrelor Market, By Indication:
Acute Coronary Syndrome
Ischemic Stroke
Global Ticagrelor Market, By Distribution Channel:
Hospital pharmacies
Retail Pharmacies
Online Pharmacies
Global Ticagrelor Market, By Region:
North America
By Country:
U.S.
Canada
By Strength:
60 mg
90 mg
By Indication:
Acute Coronary Syndrome
Ischemic Stroke
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Strength:
60 mg
90 mg
By Indication:
Acute Coronary Syndrome
Ischemic Stroke
By Distribution Channel:
Hospital pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Strength:
60 mg
90 mg
By Indication:
Acute Coronary Syndrome
Ischemic Stroke
By Distribution Channel:
Hospital pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Strength:
60 mg
90 mg
By Indication:
Acute Coronary Syndrome
Ischemic Stroke
By Distribution Channel:
Hospital pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Strength:
60 mg
90 mg
By Indication:
Acute Coronary Syndrome
Ischemic Stroke
By Distribution Channel:
Hospital pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Strength:
60 mg
90 mg
By Indication:
Acute Coronary Syndrome
Ischemic Stroke
By Distribution Channel:
Hospital pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
C.H. Boehringer Sohn AG & Ko. KG *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Pfizer Inc.
Eli Lilly and Company
AstraZeneca plc
Natco Pharma Limited
ANHUI HAIKANG PHARMACEUTICAL CO., LTD.
Avra Laboratories Pvt. Ltd.
Sun Pharmaceutical Industries Ltd
“*” marked represents similar segmentation in other categories in the respective section.